Medium-Term Environmental Action Plan 21–25

The Mitsubishi Tanabe Pharma Group views environmental measures as an important management issue and has identified “environment-friendly business” as a materiality that contributes to the SDGs, and has formulated the Medium-Term Environmental Action Plan 21–25, which established six environmental themes, including monitoring indicators, as priority items.

Achievement Status of Medium-Term Environmental Action Plan 21–25

Targets

Principal Initiatives and Results in Fiscal 2024

Environmental SDGs

Energy conservation and global warming mitigation
  • Reduce GHG emissions by 58% by fiscal 2025 compared to fiscal 2019 (Global: Scope 1 + 2)
  • 35% reduction compared to fiscal 2019

sdgs07e　Goal 7

sdgs13e　Goal 13
  • Promote reduction of supply chain CO2 emissions
  • Scope 3 was tracked and disclosed in the Sustainability Report
  • Appropriately manage fluorocarbons
  • Amount leaked 160 kg (649 t-CO2eq)

Reduction of waste, recycling and reuse of resources
  • Reduce amount of waste generated by 30% by 2025 compared to fiscal 2019 (Japan)
  • Reduce amount of final waste disposed by 50% by 2025 compared to fiscal 2019 (Japan)

Compared to fiscal 2019

  • 40% reduction of waste generated in Japan
  • 78% reduction in final waste disposal in Japan

sdgs12e　Goal 12
  • Promote reduction of plastic usage and recycling of waste
  • Plastic waste emissions in Japan 196 tons
    *Emission volume is the total for the Group
  • 30% recycling rate

Effective use of water resources
  • Reduce volume of water usage by 15% by 2025 compared to fiscal 2019 (Global)
  • 45% reduction compared to fiscal 2019

sdgs06e　Goal 6

Prevention of environmental pollution
  • Continue to maintain COD emissions at current levels compared to fiscal 2019 (Japan)
  • 58% reduction compared to fiscal 2019

sdgs06e　Goal 6

 

sdgs12e　Goal 12
  • Reduce PRTR emission substances (Japan)
  • 56% reduction compared to fiscal 2019

Preservation of biodiversity
  • Promote understanding and reduce environmental impact on biodiversity
  • Promote biodiversity preservation efforts
  • Awareness of environmental impact through monitoring, etc., and measures to reduce impact
  • Participation in activities to preserve the natural environment, such as tree-planting on Mt. Ikoma in Osaka Prefecture, and preservation of rural landscapes in the Hachioji-Takiyama area of Tokyo

sdgs15e　Goal 15

Enhancement of environmental management
  • Strengthen environmental risk management, promote compliance, and prevent environmental accidents
  • Performance of environmental audits
  • Performance of environmental education and training
  • Appropriate response to environmental trouble and revisions to environmental laws and regulations
  • Maintain zero environmental accidents and violations of laws and regulations
  • While maintaining zero environmental accidents and violations of laws and regulations for eight years

Material Balance

The figures below show the amount of resources (inputs) directly consumed and the environmental impact (outputs) discharged by our business activities in fiscal 2024.

  • Excluding PRTR substances
  • Excluding PRTR subtances

New Medium-Term Environmental Action Plan 25–30

The Group has formulated a new Medium-Term Environmental Action Plan with 2030 as the goal.

New Medium-Term Environmental Action Plan 25–30

Important theme

Targets

Energy conservation and global warming mitigation
  • 69% reduction in greenhouse gas emissions over fiscal 2019 by fiscal 2030 (Global: Scope 1 + 2)
  • Promotion of reduction in supply chain greenhouse gas emissions
  • Promote appropriate management of fluorocarbons

Reduction of waste, recycling and reuse of resources
  • 10% reduction in amount of final disposal to waste over fiscal 2023 by fiscal 2030 (Global)
  • Increase of waste recycling rate to at least 65% by fiscal 2030 (Global)
  • Increase of waste plastic recycling rate to at least 65% by fiscal 2030 (Japan)

Effective use of water resources
  • 5% reduction in volume of water usage over fiscal 2023 by fiscal 2030 (Global)

Prevention of environmental pollution
  • 2-ton reduction in COD emissions over fiscal 2023 (Global)
  • Promotion of prevention of atmospheric and water pollution
  • Reduction in PRTR substances emission amount

Preservation of biodiversity
  • Promotion of identification and reduction of environmental load impacting biodiversity
  • Promotion of biodiversity conservation initiatives

Enhancement of environmental management
  • Enhancement of environmental risk management and promotion of compliance and prevention of environmental accidents
  • Continuation of zero environmental accidents and environment-related compliance cases (serious violations and violations)

Participation in Initiatives and Industry Group Activities

The Group participates in the following initiatives and industry group activities to solve social issues related to the environment and continues to be a company that is trusted by society.

Activities of Japan Climate Initiative (JCI)*

In an effort to achieve the decarbonized society required in the Paris Agreement, the Company has participated in the Japan Climate Initiative* since 2021. Additionally, JCI has been sending regular messages to encourage the Japanese Government to achieve the target of limiting the rise in global temperatures to the 1.5°C set out in the Paris Accords, and in fiscal 2024 endorsed a message calling on the Japanese government to set ambitious targets for 2035 that are consistent with the 1.5°C goal.

  • The Japan Climate Initiative (JCI) is a network comprised of various entities (non-government actors) besides the national government that includes companies, municipalities, and NGOs, aiming to achieve a carbon-free society. Companies that are actively working on climate change measures are joining in support of the JCI Declaration which states, “Joining the front line of global trend for decarbonization from Japan.”

Activities of Pharmaceutical Industry Associations

The Company participates in environmental activities conducted by the Federation of Pharmaceutical Manufacturers’ Associations of Japan and the Japan Pharmaceutical Manufacturers Association, and is working to promote a recycling-oriented society and carbon neutrality in the pharmaceutical industry.

Note: Information on this page pertains to activities and results for fiscal 2024.